BR112018015783A2 - biomarcadores de copanlisibe - Google Patents

biomarcadores de copanlisibe

Info

Publication number
BR112018015783A2
BR112018015783A2 BR112018015783A BR112018015783A BR112018015783A2 BR 112018015783 A2 BR112018015783 A2 BR 112018015783A2 BR 112018015783 A BR112018015783 A BR 112018015783A BR 112018015783 A BR112018015783 A BR 112018015783A BR 112018015783 A2 BR112018015783 A2 BR 112018015783A2
Authority
BR
Brazil
Prior art keywords
biomarkers
lnhs
copanlisib
respond
patients
Prior art date
Application number
BR112018015783A
Other languages
English (en)
Inventor
Pena Carol
Cheng Jie
Köchert Karl
Liu Li
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of BR112018015783A2 publication Critical patent/BR112018015783A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

biomarcadores de copanlisibe a presente invenção refere-se a biomarcadores com base na perfilação da expressão gênica que podem discriminar entre pacientes que respondem a e/ou com maior sobrevida livre de progressão e pacientes que não respondem a e/ou com menor sobrevida livre de progressão do tratamento com copanlisibe em linfoma incluindo lnhs e llcs indolentes e agressivos. a presente invenção se refere ao uso de genes do bcr, pi3k, nfkb, il6, inflamação e processos estromais como biomarcadores preditivos para vários cânceres humanos incluindo, entre outros, lnhs.
BR112018015783A 2016-02-01 2017-01-31 biomarcadores de copanlisibe BR112018015783A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662289715P 2016-02-01 2016-02-01
PCT/EP2017/051988 WO2017134030A1 (en) 2016-02-01 2017-01-31 Copanlisib biomarkers

Publications (1)

Publication Number Publication Date
BR112018015783A2 true BR112018015783A2 (pt) 2018-12-26

Family

ID=57984907

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018015783A BR112018015783A2 (pt) 2016-02-01 2017-01-31 biomarcadores de copanlisibe

Country Status (16)

Country Link
US (1) US20190382839A1 (pt)
EP (1) EP3411498A1 (pt)
JP (1) JP2019512003A (pt)
KR (1) KR20180104129A (pt)
CN (1) CN109072307A (pt)
AU (1) AU2017215096A1 (pt)
BR (1) BR112018015783A2 (pt)
CA (1) CA3012951A1 (pt)
CL (1) CL2018002070A1 (pt)
MA (1) MA43958A (pt)
MX (1) MX2018009367A (pt)
PH (1) PH12018501622A1 (pt)
SG (2) SG10202007322PA (pt)
SV (1) SV2018005729A (pt)
TN (1) TN2018000272A1 (pt)
WO (1) WO2017134030A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3018127A1 (en) 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
EP3268490B1 (en) 2015-03-09 2020-07-08 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations
CN108884098B (zh) 2016-03-08 2021-09-14 拜耳制药股份公司 2-氨基-N-[7-甲氧基-2,3-二氢咪唑并[1,2-c]喹唑啉-5-基]嘧啶-5-甲酰胺类
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
CA3037626A1 (en) 2016-09-23 2018-03-29 Bayer Pharma Aktiengesellschaft Combination of pi3k-inhibitors
US11185549B2 (en) 2017-06-28 2021-11-30 Bayer Consumer Care Ag Combination of a PI3K-inhibitor with an androgen receptor antagonist
EP3498266A1 (en) * 2017-12-15 2019-06-19 Bayer Consumer Care AG Formulations of copanlisib
CU24607B1 (es) * 2017-09-08 2022-06-06 Bayer Consumer Care Ag Sólido estable, liofilizado, que contiene copanlisib, útil para dilución y aplicaciones terapéuticas

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
ES2481672T3 (es) * 2003-07-17 2014-07-31 Pacific Edge Limited Marcadores para la detección del cáncer gástrico
EP2508525A1 (en) 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
CA2908776C (en) * 2013-04-08 2021-08-10 Bayer Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for treating lymphomas
DK3543355T3 (da) * 2013-06-20 2021-03-01 Taiho Pharmaceutical Co Ltd Fremgangsmåde til forudsigelse af terapeutisk effektivitet for pi3k/akt/mtor-hæmmer på basis af phlda1- eller pik3c2b-ekspression
US20150320754A1 (en) * 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies

Also Published As

Publication number Publication date
PH12018501622A1 (en) 2019-06-03
CL2018002070A1 (es) 2018-11-16
MA43958A (fr) 2018-12-12
WO2017134030A1 (en) 2017-08-10
KR20180104129A (ko) 2018-09-19
MX2018009367A (es) 2018-11-09
EP3411498A1 (en) 2018-12-12
TN2018000272A1 (en) 2020-01-16
JP2019512003A (ja) 2019-05-09
SG11201806512VA (en) 2018-08-30
SV2018005729A (es) 2018-12-05
AU2017215096A1 (en) 2018-08-09
CA3012951A1 (en) 2017-08-10
US20190382839A1 (en) 2019-12-19
SG10202007322PA (en) 2020-09-29
CN109072307A (zh) 2018-12-21

Similar Documents

Publication Publication Date Title
BR112018015782A2 (pt) biomarcadores de copanlisibe
BR112018015783A2 (pt) biomarcadores de copanlisibe
TWD178500S (zh) 護膚器
CO2017000300A2 (es) Moléculas con especificidad para cd45 y cd79
TWD200261S (zh) 空氣清淨機（一）
GT201500249A (es) Terapia de combinación
TWD170218S (zh) 指式血氧機
TWD190432S (zh) 鼻管
CL2013003324A1 (es) Composicion que comprende quimioterapia con paclitaxel y carboplatino y un oligonucleotido anti-clusterina; uso de la composición para el tratamiento de un paciente humano que padece cancer de pulmón.
BR112018006393A2 (pt) método para classificar um linfoma difuso de grande célula b (dlbcl), uma ou mais mídias de armazenamento legíveis por computador, sistema de computação adaptado e kit
CL2019002323A1 (es) Anticuerpo dirigido a il-13ra2 y su uso.
TWD198876S (zh) 水平儀
TR201902547T4 (tr) Oksi̇dati̇f stresli̇ hastalarda parati̇roi̇d hormonunun ölçüm araçlari ve yöntemleri̇
BR112015016995A2 (pt) uso de agonistas de receptores alfa 7 nicotínico de acetilcolina para a facilitação do surgimento da anestesia geral
TWD180477S (zh) 生物晶片之部分
TWD173712S (zh) 自動鉛筆
TWD167999S (zh) 氣球支架
TWD188189S (zh) 多波道測量儀器殼體之部分
UY34758A (es) USO INTRAUTERINO DE 18-METIL-15B(Beta),16B(Beta)-METILEN-19-NOR-20-ESPIROX-4-EN-3-ONAS, SISTEMAS INTRAUTERINOS QUE CONTIENEN 18-METIL-15B(Beta),16B(Beta)-METILEN-19-NOR-20-ESPIROX-4-EN-3-ONAS, ASÍ COMO SU USO EN LA ANTICONCEPCIÓN Y TERAPIA GINECOLÓGICA.
TWD169177S (zh) 燈測試器之部分
TWD195773S (zh) 車輛
TWD177036S (zh) 空氣清淨機
TWD179743S (zh) 照護用廁所
PL410822A1 (pl) Trójskładnikowa kombinacja do zastosowania w leczeniu skojarzonym niedrobnokomórkowego raka płuc
TWD186713S (zh) 拖鞋之部分

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2707 DE 22/11/2022.